Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7I64Z)

Drug Name
Almogran Drug Info
Synonyms
Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1]
Therapeutic Class
Antimigraine Agents
Cross-matching ID
PubChem CID
123606
ChEBI ID
CHEBI:520985
CAS Number
CAS 154323-57-6
TTD Drug ID
DM7I64Z
ACDINA Drug ID
D00021

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting 5-HT 1D receptor (HTR1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Metergolin DMJFP6G Hyperprolactinaemia 5A60.1 Approved [5]
Eletriptan DMW649X Migraine 8A80 Approved [6]
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [6]
Frovatriptan DM7RE8P Migraine 8A80 Approved [6]
Sumatriptan DMVYXR8 Cluster headache 8A81.0 Approved [7]
Rizatriptan DMDJMA3 Migraine 8A80 Approved [8]
Neu-P11 DMIQDFW Alzheimer disease 8A20 Phase 2 [9]
FKB01MD DM2O7NM N. A. N. A. Phase 2 [10]
NXN-188 DMMBAIH Migraine 8A80 Phase 2 [11]
TGBA01AD DMJ2FTU Mood disorder 6A60-6E23 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Flavin-containing monooxygenase 3 (FMO3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [13]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [15]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [16]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [17]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [18]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [19]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [20]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [21]
Clozapine DMFC71L Schizophrenia 6A20 Approved [22]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Amine oxidase A (MAOA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [23]
Quercetin DM3NC4M Obesity 5B81 Approved [24]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [25]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [26]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [27]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [28]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [29]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [13]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [30]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [31]
Leflunomide DMR8ONJ Arthritis FA20 Approved [32]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [14]
Folic Acid DMEMBJC Colorectal carcinoma Approved [33]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [34]
Cytarabine DMZD5QR Acute lymphoblastic leukaemia 2A85 Approved [35]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [36]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [37]
Sibutramine DMFJTDI Obesity 5B81 Approved [38]
Eletriptan DMW649X Migraine 8A80 Approved [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amodiaquine DME4RA8 Malaria 1F40-1F45 Approved [39]
Riluzole DMECBWN Amyotrophic lateral sclerosis 8B60.0 Approved [40]
Flutamide DMK0O7U Prostate cancer 2C82.0 Approved [41]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [42]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [43]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [44]
Ethacrynic acid DM60QMR Edema MG29 Approved [45]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [46]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [47]
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [49]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [50]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [51]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [52]
Capsaicin DMGMF6V Back pain ME84.Z Approved [53]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [54]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [55]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [54]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [50]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [57]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [58]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [57]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [58]
Sulfinpyrazone DMEV954 Gout FA25 Approved [59]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [57]
Zafirlukast DMHNQOG Asthma CA23 Approved [57]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [57]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [60]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [62]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [62]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [62]
Capsaicin DMGMF6V Back pain ME84.Z Approved [53]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [63]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [55]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [64]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [65]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [66]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [56]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [67]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [49]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [68]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [51]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [54]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [54]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [69]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [70]
Capsaicin DMGMF6V Back pain ME84.Z Approved [71]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [72]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [73]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [74]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [75]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [76]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [77]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [78]
Capsaicin DMGMF6V Back pain ME84.Z Approved [53]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [54]
Quinidine DMLPICK N. A. N. A. Approved [79]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [80]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1D receptor (HTR1D) TT6MSOK 5HT1D_HUMAN Agonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Regulation of Drug Effects [3]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Biotransformations [3]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Biotransformations [3]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Biotransformations [3]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Biotransformations [3]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Biotransformations [3]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [3]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Biotransformations [3]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3) OTA6HYBA GBB3_HUMAN Drug Response [4]

References

1 Drug information of Almogran, 2008. eduDrugs.
2 Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
3 Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
4 G protein beta3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007 Oct;82(4):396-401. doi: 10.1038/sj.clpt.6100159. Epub 2007 Mar 14.
5 Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
8 An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
9 Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Company report (NeurAxon)
12 Company report (Fabrekramer)
13 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
14 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
15 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
16 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
17 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
18 Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos. 2004 Nov;32(11):1247-53. doi: 10.1124/dmd.104.000026. Epub 2004 Jul 30.
19 Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J Pharmacol Exp Ther. 2007 Jan;320(1):266-73. doi: 10.1124/jpet.106.112268. Epub 2006 Oct 18.
20 Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res. 2004 Dec 15;10(24):8357-62. doi: 10.1158/1078-0432.CCR-04-1073.
21 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
22 Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos. 2008 Dec;36(12):2547-55. doi: 10.1124/dmd.108.023671. Epub 2008 Sep 22.
23 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
24 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
25 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
26 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
27 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
28 Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
29 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
30 Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem. 2011 Oct 27;54(20):7127-37.
31 G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics. 2008 Oct;9(10):1429-36. doi: 10.2217/14622416.9.10.1429.
32 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
33 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
34 Proteomic analysis of human adipose tissue after rosiglitazone treatment shows coordinated changes to promote glucose uptake. Obesity (Silver Spring). 2010 Jan;18(1):27-34. doi: 10.1038/oby.2009.208. Epub 2009 Jun 25.
35 Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
36 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
37 Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol. 2003 Dec;6(4):339-46. doi: 10.1017/S1461145703003663.
38 Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet Genomics. 2009 Sep;19(9):730-3. doi: 10.1097/FPC.0b013e3283307cf1.
39 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
40 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
41 Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
42 Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
43 Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
44 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
45 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
46 Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
47 The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
48 Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
49 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
50 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
51 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
52 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
53 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
54 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
55 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
56 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
57 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
58 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
59 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
60 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
61 Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
62 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
63 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
64 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
65 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
66 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
67 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
68 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
69 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
70 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
71 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
72 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
73 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
74 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
75 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
76 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
77 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
78 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
79 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
80 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.